Oligonucleotide drugs such as ASOs, siRNAs, miRNAs, and aptamers are emerging as alternate RNA therapeutics to target previously undruggable targets through gene inhibition, addition, replacement, or editing. RNAscope™ in situ hybridization technology enables the specific detection of many RNA types including endogenous and synthetic small RNAs. ACD’s miRNAscope™ and RNAscope™ Plus assays specifically allow for detection of small oligonucleotide sequences alone or in combination with other RNA or DNA probes. With our latest multiomics offerings our assays can be utilized to visualize both RNA and protein biomarkers and helps assess on- target and off-target effects. Overall, the suite of assays can provide precise and comprehensive visual insights on the spatial distribution, expression, and functional efficacy of RNA drug candidates within intact tissues along with other endogenous RNA and protein markers.



In this webinar, we will discuss how ACD's Professional Assay Services (PAS) team can partner with you to visualize and quantify the biodistribution and efficacy of your oligonucleotide therapy in tissue samples, for any disease, with single-cell and single-molecule precision. Our RNAscope technology experts in the PAS team can assist you in evaluating the therapeutic efficacy of small RNA drug candidates, optimizing drug development strategies, and advancing promising RNA therapies.